Pradaxa Lawsuit News: FDA Notes Higher Risk of Gastrointestinal Bleeding With Pradaxa, Bernstein Liebhard LLP Report

Share Article

The Firm is evaluating Pradaxa lawsuits on behalf of individuals who allegedly suffered serious gastrointestinal hemorrhaging and other episodes of uncontrollable internal bleeding due to Pradaxa.

Free Case Review
Our Firm has heard from numerous Pradaxa patients who allegedly suffered serious gastrointestinal bleeding similar to the issues described in the FDA’s communication.

As Pradaxa lawsuits ( continue to mount in U.S. courts, Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) has issued a new Drug Safety Communication pertaining to the blood-thinning drug. According to the May 13th alert, a recently completed study of more than 134,000 Medicare patients found that Pradaxa was associated with a higher rate of major gastrointestinal bleeding compared to warfarin. However, the Medicare study also noted a lower rate of stroke and death among patients taking Pradaxa.*

“Our Firm has heard from numerous Pradaxa patients who allegedly suffered serious gastrointestinal bleeding similar to the issues described in the FDA’s communication. This complication is also among the injuries alleged in thousands of Pradaxa lawsuit filings,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case evaluations to individuals who allegedly experienced serious Pradaxa bleeding side effects.

Pradaxa Bleeding Litigation
According to court documents, at least 2,467 Pradaxa lawsuits have been filed in U.S. courts on behalf of individuals who allegedly suffered uncontrollable internal bleeding due to their use of Pradaxa. The majority of these claims are pending in a federal multidistrict litigation now underway in U.S. District Court, Southern District of Illinois, where trials are expected to get underway this fall. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

Among other things, all of the complaints pending in the federal proceeding similarly allege that Boehringer Ingelheim did not provide doctors and patients with adequate warnings regarding the lack of an antidote to reverse potential Pradaxa bleeding side effects. The lawsuits further claim that Pradaxa was wrongfully touted as an improvement over warfarin, and point out that the internal bleeding that sometimes occurs with warfarin can be stopped simply via the administration of vitamin K.

Pradaxa was first approved by the U.S. Food & Drug Administration (FDA) in 2010. In February, 7 Action News in Detroit revealed that the FDA has received reports of 12,494 injuries and 1,158 deaths among Pradaxa users since the blood thinner was launched in the U.S. Many of these cases detailed episodes of uncontrollable internal bleeding among Pradaxa patients.**

Alleged victims of Pradaxa bleeding side effects may be entitled to file their own Pradaxa lawsuit against Boehringer Ingelheim. To learn more about this ongoing litigation, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to schedule a free, no obligation case review.

*, FDA, May 13, 2014
**, 7 Action News, February 25, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website